INTERLEUKIN-18 PROMOTER GENE POLYMORPHISMS
ARE NOT ASSOCIATED WITH MYOCARDIAL INFARCTION
IN TYPE 2 DIABETES IN SLOVENIA
Kariž S1*, Petrovič D2
*Corresponding Author: Stojan Kariž, Department of Internal Medicine, General Hospital Izola, Polje
35, Izola 6310, Slovenia; Tel.: +386-5-660-6480; Fax: +386-660-6305; E-mail: stojan.kariz@siol.net
page: 3
|
|
REFERENCES
1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340(2): 115-126.
2. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998; 41(10): 1241-1248.
3. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420(6917) :868-874.
4. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med. 2000; 342(14): 1040-1042.
5. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002; 195(2): 245-257.
6. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001; 104(104): 1598-1603.
7. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(–/–)mice through release of interferon-γ. Circ Res. 2002; 90(2): e34-e38.
8. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A. Interleukin- 18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001; 89(7): e41-e45.
9. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, Chvatchko Y, Tedgui A. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart. 2002; 88(5): 467-469.
10. Esposito K, Nappo F, Giugliano D, Di Palo C, Ciotola M, Barbieri M, Paolisso G, Giugliano D. Cyokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care. 2003; 26(5): 1647.
11. Aso Y, Okumura KI, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimamedia wall thickness in patients with type 2 diabetes.
Diabetes Care. 2003; 26(9): 2622-2627.
12. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002; 106:(16): 2067-2072.
13. Giedraitis V, He B, Huang WX, Hillert J. Cloning and
mutation analysis of the human IL-18 promoter: a possible
role of polymorphisms in expression regulation. J
Neuroimmunol. 2001; 112(1-2): 146-152.
14. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C, Poirier O, Perret C, Munzel T, Rupprecht HJ, Lackner K, Cambien F, Blankenberg S, for the AtheroGene Investigators. Genetic analysis of the interleukin-18 aystem highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation. 2005; 112(5): 643-650.
15. Hernesniemi JA, Karhunen PJ, Rontu R, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Pessi T, Hurme M, Lehtimäki T. Interleukin-18 promoter polymorphism associates with the occurrence of sudden cardiac death among Caucasian males: The Helsinki Sudden Death Study. Atherosclerosis. 2008; 196(2): 643-649.
16. Liu W, Tang Q, Jiang H, Ding X, Liu Y, Zhu R, Tang Y, Li B, Wei M. Promoter polymorphism of inerleukin- 18 in angiographically proven coronary artery disease. Angiology. 2009; 60(2): 180-185.
17. Kretowski A, Mironczuk K, Karpinska A, Bojaryn U,Kinalski M, Puchalski Z, Kinalska I. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes. 2002; 51(11): 3347-3349.
18. Bossu P, Ciaramella A, Moro ML, Bellincampi L, Bernardini S, Federici G, Trequattrini A, Macciardi F, Spoletini I, Di Iulio F, Caltagirone C, Spalletta G. Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2007; 78(8): 807-811.
19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26(Suppl 1): S5-S20.
20. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-- a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000; 36(3): 959-969.
21. Szeszko JS, Howson JM, Cooper JD, Walker NM,
Twells RC, Stevens HE, Nutland SL, Todd JA. Analysis of polymorphisms of the interleukin-18 gene in type 1 diabetes and Hardy-Weinberg equilibrium testing. Diabetes. 2006; 55(2): 559-562.
22. Ford E. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999; 22(12): 1971-1977.
23. Schulze M, Rifai N, Rimm E, Stampfer M, Li T, Hu F. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004; 27(4): 889-894.
24. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care. 2006; 29(2): 329-333.
25. Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, Wada J, Itoshima T, Makino H. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care. 2005; 28(12): 2890-2895.
26. Troseid M, Seljeflot I, Hjerkinn EM, Arnesen H. Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care. 2009; 32(3): 486-492.
27. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Illig T, Martin S, Herder C. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes. 2005; 54(10): 2932-2938.
28. Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol. 2005; 25(4): 791-796.
29. Rosso R, Roth A, Herz I, Miller H, Keren G, George J. Serum levels of interleukin-18 in patients with stable and unstable angina pectoris. Int J Cardiol. 2005; 98(1):45-48.
30. Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6.
Atherosclerosis. 2006; 188(2): 450-454.
31. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht Interleukin 18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002; HJ. 106(1): 24-30.
32. Blankenberg S, Luc G, Ducimetière P, Arveiler D, FerrièresJ, Amouyel P, Evans A, Cambien F, Tiret L, on behalf of the PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men:The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003; 108(20): 2453- 2459.
33. Arimitsu J, Hirano T, Higa S, Kawai M, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Hagiwara K, Ohgawara T, Kuwabara Y, Kawase I, Tanaka T. IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem Biophys Res Commun. 2006; 342(4): 1413-1416.
34. Hernesniemi JA, Karhunen PJ, Oksala N, Kähönen M, Levula M, Rontu R, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Hurme M, Lehtimäki T. Interleukin 18 gene promoter polymorphism: a link between hypertension
and pre-hospital sudden cardiac death: the Helsinki Sudden Death Study. Eur Heart J. 2009; 30(23): 2939-2946. 35. Kathiresan S, Newton-Cheh C, Gerszten RE. On the interpretation of genetic association studies. Eur Heart J. 2004; 25(16): 1378-1381.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
